Dalteparin Sodium
The antithrombotic effect of dalteparin sodium is dependent on its ability to potentiate the inhibition of Factor Xa and thrombin by antithrombin(AT). It has a relatively higher ability to potentiate Factor Xa inhibition than to prolong plasma clotting time (APTT). It has a smaller effect on platelet function and palatelet adhesion than heparin, and thus has only a small effect on primary haemostasis.Unstable coronary artery disease, i.e. unstable angina and non Q-wave myocardial infarction. Treatment of acute deep venous thrombosis. Prevention of clotting in the extracorporeal system during haemodialysis and haemofilteration in connection with acute renal failure or chronic renal insuffciency.
Unstable coronary artery disease. 120IU/kg body weight is administered subcutaneouly twice daily. Maximum dose is 10,000 IU/12 hrs. Treatment should be continued for at least 6 days or longer.
Hypersensitivity. Acute gastroduodenal ulcer and cerebral haemorrhage. Severe coagulation disorders. Septic endocarditis injuries to and operations on the central nervous system, eyes and ears.
Thrombocytopenia and platelet defects, severe liver and kidney insufficences. uncontrolled hypertension, hypertensive or diabetic retinopathy pregnancy.
Bleeding at high dosage. Subcutaneous haematomas at injection site. Thrombocytopenia, skin necrosis.
Concomitant medication with effect on haemostasis, such as ASA, NSAID's, vitamin-K antagonists and Dextran, may enhance the anticoagulant effect. However, unless specifically contrindicated patients with unstable coronary artery disease, i.e. unstable angina and non Q-wave myocardial infarction, should receive oral low dose acetylsalicylic acid.
